Amarin (AMRN) Competitors

Amarin (NASDAQ:AMRN) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability.

Is AMRN or ELVN more profitable?

Enliven Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -41.07%. Amarin's return on equity of -17.21% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-41.07%	-17.21%	-12.16%
Enliven Therapeutics	N/A	-31.84%	-30.09%

Do institutionals and insiders hold more shares of AMRN or ELVN?

22.3% of Amarin shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 3.3% of Amarin shares are owned by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media refer more to AMRN or ELVN?

In the previous week, Enliven Therapeutics had 6 more articles in the media than Amarin. MarketBeat recorded 8 mentions for Enliven Therapeutics and 2 mentions for Amarin. Amarin's average media sentiment score of 0.55 beat Enliven Therapeutics' score of 0.32 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community believe in AMRN or ELVN?

Amarin received 829 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 88.24% of users gave Enliven Therapeutics an outperform vote while only 73.20% of users gave Amarin an outperform vote.

Company	Underperform	Outperform
Amarin	Outperform Votes 844 73.20%	Underperform Votes 309 26.80%
Enliven Therapeutics	Outperform Votes 15 88.24%	Underperform Votes 2 11.76%

Do analysts rate AMRN or ELVN?

Amarin currently has a consensus target price of $7.00, suggesting a potential downside of 56.36%. Enliven Therapeutics has a consensus target price of $39.60, suggesting a potential upside of 87.15%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enliven Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better earnings and valuation, AMRN or ELVN?

Amarin has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$214.11M	1.55	-$82.18M	-$3.64	-4.41
Enliven Therapeutics	N/A	N/A	-$89.02M	-$1.92	-11.02

Which has more volatility and risk, AMRN or ELVN?

Amarin has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Summary

Enliven Therapeutics beats Amarin on 10 of the 17 factors compared between the two stocks.